The definitive intelligence briefing on the brain-computer interface industry — covering market size, venture funding, clinical trials, human implant counts, regulatory milestones, and the 2026 outlook. Compiled by bciintel.com from primary sources including ClinicalTrials.gov, FDA databases, and company disclosures.
2026 marks a critical inflection point for the brain-computer interface industry. For the first time, multiple companies are simultaneously enrolling patients across multiple countries. Neuralink has implanted 21 people across four nations. Synchron has completed its US feasibility trial and is preparing a pivotal study targeting FDA Pre-Market Approval. Precision Neuroscience holds FDA 510(k) clearance and is moving toward chronic implants.
Venture investment has reached record levels — more than $1.6B raised in 2025–2026 YTD — driven by high-profile rounds from Neuralink ($650M), Synchron ($200M), Merge Labs ($252M), and Science Corporation ($230M). The market is bifurcating: clinical-stage invasive BCIs targeting serious medical conditions, and consumer-facing non-invasive neurotechnology for productivity and gaming.
The BCI market encompasses a broad range of technologies: commercial deep brain stimulation (Medtronic, Abbott, Boston Scientific) currently constitutes the largest segment by revenue, driven by established markets in Parkinson's disease and essential tremor. The fastest-growing segments are clinical-stage implantable communication BCIs and non-invasive consumer EEG devices.
| Company | Round | Amount | Lead Investor(s) | Date |
|---|---|---|---|---|
| Neuralink | Series E | $650M | Jun 2025 | |
| Merge Labs | Seed | $252M | Jan 2026 | |
| Science Corporation | Series C | $230M | Mar 2026 | |
| Synchron | Series D | $200M | Nov 2025 | |
| Science Corporation | Series B | $103.6M | Mar 2025 |
| Sponsor | Study | Device | Enrolled / Target | Phase | Status |
|---|---|---|---|---|---|
| Neuralink | N1 Implant | 21 / 30 | feasibility | RECRUITING | |
| Neuralink | N1 Implant | 3 / 3 | feasibility | RECRUITING | |
| Neuralink | N1 Implant | 7 / 10 | feasibility | RECRUITING | |
| Synchron | Stentrode (next-generation) | 0 / 60 | pivotal | NOT YET RECRUITING | |
| Precision Neuroscience | Layer 7 | 50 / 100 | feasibility | ACTIVE | |
| BrainGate Consortium / Massachusetts General Hospital | Utah Array | 14 / 27 | feasibility | ACTIVE | |
| Paradromics | Connexus Direct | 1 / 2 | feasibility | RECRUITING | |
| University of California San Francisco | High-density ECoG | 4 / 10 | feasibility | RECRUITING |
| Device | Type | Electrodes | FDA Status | Stage |
|---|---|---|---|---|
| N1 Implant (Telepathy) | intracortical | 1,024 | IDE | investigational |
| Blindsight Visual Prosthesis | intracortical | 1,024 | BREAKTHROUGH | investigational |
| Stentrode | endovascular | 16 | BREAKTHROUGH | investigational |
| Connexus Direct Data Interface | intracortical | 1,684 | IDE | investigational |
| Utah Array (NeuroPort Electrode 96) | intracortical | 96 | 510K-CLEARED | investigational |
| MoveAgain BCI System | intracortical | 96 | BREAKTHROUGH | investigational |
| Neuralace | intracortical | 10,000 | NONE | r&d |
| BrainGate Neural Interface System | intracortical | 96 | IDE | investigational |
Companies with active human trials, FDA approvals, or commercial products. Represent >90% of disclosed BCI investment.
Well-funded companies with FDA IDE applications filed or significant research progress. Expect human trials within 1–3 years.
Consumer-focused or early-stage companies. Non-invasive EEG platforms, emerging modalities, and novel approaches.
This report is compiled by bciintel.com from primary and secondary sources. Data is refreshed continuously by an autonomous agent that monitors news, regulatory databases, and academic publications. Numbers in this report reflect the state of the industry as of March 2026.
The global brain-computer interface market was valued at approximately $2.8 billion in 2025 and is estimated at $3.2 billion in 2026. Projections from Grand View Research, MarketsandMarkets, and Global Market Insights put the market at $6–12 billion by 2030, representing a 15–18% CAGR. Key growth drivers include clinical BCI approvals, expanding DBS indications, non-invasive consumer neurotechnology, and increasing VC investment.
The BCI industry raised over $1.6 billion in disclosed VC and institutional funding in 2025–2026 YTD. The largest single round was Neuralink's $650M Series E at a $9 billion valuation in June 2025. Other major rounds include Synchron's $200M Series D (November 2025), Merge Labs's $252M seed (January 2026), and Science Corporation's $230M Series C (March 2026). Total disclosed BCI investment since 2018 exceeds $3 billion.
Synchron is the furthest along the FDA regulatory pathway for a chronically-implanted communication BCI, with its COMMAND early feasibility study completed (6/6 patients meeting primary safety endpoint) and a pivotal trial targeting 2026 enrollment. NeuroPace (RNS System) and Medtronic (DBS) already hold commercial PMA approvals. Precision Neuroscience holds FDA 510(k) clearance for temporary (up to 30 days) implantation. Neuralink has IDE approval and is expanding its PRIME feasibility study to 30 participants before pivotal trial planning.
Key BCI milestones to watch in 2026 include: (1) Neuralink PRIME study completing enrollment (target: 30 patients) and submitting NEJM manuscript; (2) Synchron's pivotal trial beginning enrollment across 4+ US sites; (3) Neuralink's Blindsight visual prosthesis first-in-human implant; (4) Paradromics' Connect-One first chronic speech restoration implant; (5) Precision Neuroscience's first-in-human chronic wireless implant; (6) Science Corporation CE mark approval for PRIMA retinal implant in Europe; (7) Merge Labs' first technical demonstrations of its ultrasound-based BCI.
Invasive BCIs require surgical implantation and include intracortical devices (electrodes penetrate brain tissue, e.g., Neuralink N1, BrainGate Utah Array), endovascular devices (delivered via blood vessel, e.g., Synchron Stentrode), and ECoG devices (placed on brain surface, e.g., Precision Neuroscience Layer 7). Non-invasive BCIs use external sensors — most commonly EEG headsets (EMOTIV EPOC, OpenBCI, Neurable MW75 Neuro) that measure scalp electrical signals. Invasive BCIs achieve significantly higher signal quality and bandwidth but require surgery. Non-invasive BCIs are safe, portable, and commercially available but have lower resolution.